FRANKLIN LAKES, N.J., Mar. 30, 2016 – BD (Becton, Dickinson and Company), a leading global medical technology company, has obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the BD BACTEC™ PEDS Plus™/F blood culture bottle in plastic, still available in glass. This marks the fourth media culture bottle available in plastic across BD’s industry-leading BD BACTEC™ platform.
The new BD BACTEC™ PEDS Plus™/F plastic blood culture bottle is designed for customer convenience for the qualitative culture and recovery of aerobic microorganisms from pediatric and non-pediatric blood specimens less than 5 mL in volume. This latest addition to BD’s family of sepsis and healthcare associated infection solutions represents BD’s continued commitment to meeting customer needs and enhancing laboratory efficiencies. The BD plastic bottle offering is smaller and lighter, allowing for easier and safer handling during collection, transport and disposal.
“We are very pleased to announce the availability of the BD BACTEC PEDS Plus/F media in a plastic bottle,” said David Hickey, vice president and general manager of Microbiology Diagnostics Systems for BD Life Sciences – Diagnostic Systems. “Sepsis, increasing at an annual rate of 8 percent to 13 percent1, continues to place tremendous public health and financial burden on our global health care communities. The availability of BD’s fourth media culture bottle in plastic demonstrates our ongoing commitment to delivering total solutions that are focused on optimizing clinical outcomes and laboratory efficiencies.”
The BD BACTEC blood culture platform, which includes the BD BACTEC™ blood culture instrument and resin media blood culture bottles, has been shown to improve bacterial recovery, facilitating changes in antibiotic treatment that facilitate antibiotic stewardship.2 For more information, please visit: www.bd.com/ds/.
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com
For more information on BD, please visit bd.com.